Introduction
The rapid expansion of antiretroviral therapy (ART) has been a cornerstone in transforming the acquired immunodeficiency syndrome (AIDS) response globally. In March 2015, the '15 by 15' target set out in the 2011 United Nations Political Declaration on HIV and AIDS was achieved ahead of the deadline. 1 The greatest gains in access to ART occurred in sub-Saharan Africa, a region with 25.5 million people living with HIV. 2 However, treatment coverage remains relatively low. In 2015, only 12.1m (47%) people living with HIV in the region were accessing ART. 2 There were 1.4m (range 1.1m-1.6m) new HIV infections and 800 000 (range 640 000-990 000) AIDS-related deaths. 2 Barring unforeseen events, the AIDS epidemic will continue to outrun the response and these figures are likely to rise. 3 To end the AIDS epidemic by 2030, the Joint United Nations Programme on HIV/AIDS (UNAIDS) has established the 90-90-90 targets for 2020 (i.e. 90% of people living with HIV to know their status; 90% of people diagnosed with HIV to be accessing treatment; and 90% of those on ART achieving viral suppression) that will prevent an estimated 21m AIDS-related deaths and 28m new HIV infections worldwide by 2030.
3 Shortly after these targets were established, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) adopted them as part of the pivot to PEPFAR 3.0. 4 Achieving these targets would require countries to align their national guidelines and programmes with the latest scientific evidence that demonstrates the benefits of immediate ART in reducing the risk of HIV-related morbidity, mortality, transmission and costs. 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 Translating scientific discovery into policy and then service delivery generally takes years. However, delays translate into missed public health opportunities to prevent illness, death and transmission and deny millions of people timely access to life-saving treatment. 
Methods
From the International Association of Providers of AIDS Care's (IAPAC) National Policy Database, 20 we collected the latest national treatment guidelines for adults and adolescents for 48 countries in sub-Saharan Africa. This database (www.hivpolicywatch.org) is current as of July 2016 and has been constructed over a 5-year period using quarterly Internet searches and direct submissions from Ministries of Health, WHO, UNAIDS, Centers for Disease Control and Prevention, United States Agency for International Development, PEPFAR, non-governmental organisations, HIV experts and members of the community. In addition to the IAPAC database, an Internet search was also done for previously published guidelines using the keywords 'country name' and 'HIV treatment or antiretroviral' and 'guidelines'. As PDF versions of national guidelines before 2005 were often not available or links to these guidelines had expired, we restricted the analysis to calculating the time lag in adoption of the WHO 2009, 2013 and 2015 guidelines.
Of the 48 countries in the sub-Saharan African region, we found 92 published national guidelines from 37 countries, representing 98% of regional HIV burden in 2015 (referred to as regional burden henceforth). . From the remaining 59 guidelines for 33 countries (97% regional burden), we abstracted information on (1) month and year of publication of the guidelines, and (2) ART eligibility criteria for asymptomatic adults living with HIV. In cases where the month of publication was not known, we assumed that the guidelines were published in June of the same calendar year. 
Results
According to the latest available published national guidelines from 33 countries, 3 countries (6% regional burden) are recommending ART according to the WHO 2015 guidelines (treatment for all). A total of 19 countries (65% regional burden) are recommending ART according to the WHO 2013 guidelines (CD4 count ≤ 500 cells/mm 
Time lag in adopting the WHO 2015 guidelines
None of the countries in sub-Saharan Africa moved to ART irrespective of CD4 count before the release of the WHO 2015 guidelines (Figure 2 ). Of the 33 countries, 3 (6% regional burden) moved to ART irrespective of CD4 count after publication of the WHO 2015 guidelines (Figure 2 ). These countries took an average of 8 (range 7-9) months to revise their national guidelines in line with the WHO 2015 recommendations.
Discussion
The national treatment guidelines are vital tools for programme design and management of people living with HIV. Timely adoption of international best practices and normative guidelines as national policies, and successful dissemination and implementation of these policies, are critical for accelerated access to ART. Guideline revisions can be complex and often involve consensus building around technical and operational issues and negotiations with internal and external stakeholders regarding budget prioritisation. Our study suggests that adoption of national treatment guidelines from sub-Saharan African countries has been very slow, with countries taking an average of 2 years to move to CD4 ≤ 350 cells/mm 3 after release of the WHO 2009 guidelines. It has been 3 years since the release of the WHO 2013 guidelines, but 11 countries, including many high-burden countries such as Nigeria and Mozambique, have not yet adopted these guidelines.
As of August 2016, after 11 months, only three countries in the region had adopted and published national guidelines reflecting the WHO 2015 recommendations, which were published in September 2015. Recent public announcements about plans to adopt 'test and treat' suggest that adoption of the WHO 2015 guidelines may be more rapid than for the WHO 2009 and 2013 guidelines. 21 However, implementation of national guidelines takes additional time which threatens to increase the delay to many years before the WHO 2015 guidelines become actual practice in the countries. Understanding these delays and considering ways to shorten the time lag from science to guideline adoption to delivery of HIV services is essential to more rapidly expand access to treatment for people living with HIV and achieving the 90-90-90 targets.
Countries with low HIV prevalence and higher HIV spending are more likely to adopt the WHO guidelines. 22 This is evident from the global trends -treatment for all has been the standard of care in 18 high-and middle-income countries with low HIV prevalence for some years. 20 On the other hand, Lesotho, Malawi and Botswana have adopted this recommendation recently. 20 Also, patterns of HIV spending in high-burden countries do not consistently reflect the new science around 'treatment as prevention'. Many sub-Saharan African countries are allocating less than 50% of their total HIV spending on care and treatment. 23 HIV spending on ART per person living with HIV is below US$200 in most of these countries. 23 Adoption and implementation of the WHO 2015 guidelines will pay off with improvement in ART coverage and reductions in illness, AIDS-related deaths and HIV transmission, and save health and other costs. 5, 6, 7 With nearly 2200 AIDS-related deaths and 3800 new infections each day, 2 translating the new science into action more quickly needs to become a major public health priority for the sub-Saharan African region. The countries in this region, which are already struggling to provide ART, will require additional funds and/or more efficient resource utilisation to make a timely move to 'treatment for all'. Given that international funding has flat-lined, countries will need to commit more funds from domestic or innovative financing sources and allocate more resources for care and treatment. 21 Additionally, investments in innovative service delivery models (e.g. community-based testing and drug dispensing, nurse-initiated ART), decreased use of CD4 count for ART initiation and monitoring, and advances in antiretroviral regimens and technology will allow more people to be on treatment with the same or even less resources.
Limitations of the study
Our study has several limitations. We concentrated solely on published national guidelines to determine the date of adoption of the WHO recommendations. Written policies might not reflect practice in countries or might have been published after a recommendation was implemented, suggesting that we might have overestimated the time lag in some cases. Even though we did a comprehensive search for all national guidelines, we might have missed some guidelines; and some guidelines may be outdated or in the process of being updated.
http://www.sajhivmed.org.za Open Access 
8
NA, not applicable; Jan, January; Feb, February; Mar, March; Apr, April; Jun, June; Jul, July; Aug, August; Oct, October; Nov, November; Dec, December.
Conclusion
Since 2000, HIV treatment has dramatically changed the natural history of the HIV epidemic. The new science showing the benefits of treatment for all 5, 6, 7 along with other prevention interventions has provided the opportunity to end AIDS by 2030. However, our study shows that it takes years for national policies to reflect the latest science and international standard of care. Even if published guidelines reflect new normative standards, implementation and access to the best care may lag. AIDS response is at a crucial juncture; the new science around treatment and the health and human rights obligation of governments calls for strategic use of resources to rapidly translate new science regarding HIV treatment into action. 24, 25 An estimated 13.4m people living with HIV are eligible but not on treatment. 2 The HIV epidemic is by no means over, and there is an urgent need to move away from the traditional 'one step at a time, business as usual' approach to guidelines production, dissemination and revision. The present analysis, which benchmarks the current pace of policy adoption, may help global and national accountability to expedite the adoption and implementation of 'treatment for all' in sub-Saharan Africa to win the fight against HIV.
